Premium
Evogliptin, a novel dipeptidyl peptidase 4 inhibitor ameliorates atherosclerosis by modulating vascular inflammatory responses
Author(s) -
Won Jong Soon,
Nguyen Phuc Anh,
Cho Min Kyung
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.lb561
Subject(s) - dipeptidyl peptidase 4 , cancer research , downregulation and upregulation , inflammation , chemistry , pharmacology , microbiology and biotechnology , medicine , endocrinology , biology , biochemistry , diabetes mellitus , type 2 diabetes , gene
Evogliptin (Suganon TM ), a potent and selective dipeptidyl peptidase 4 inhibitor, was globally approved for the treatment of type 2 diabetes mellitus. However, the effect of evogliptin on the atherosclerotic progression has not been evaluated. In the present study, we examined the effects of evogliptin on the progression of atherosclerosis and its possible mechanism of action. Evogliptin reduced high fat diet‐induced plaque area in ApoE‐knockout mouse model. Evogliptin significantly suppressed the expression of adhesion molecules including ICAM‐1 and VCAM by ox‐LDL, a proatherogenic risk factor in human endothelial cells. NF‐kB activation was dose dependently inhibited by evogliptin. PPARγ suppressed by ox‐LDL was reversed by evogliptin. The anti‐adhesive effects between endothelial cells and monocytes by evogliptin were reversed by gene knockdown of PPARγ. The present study demonstrates that evogliptin attenuates atherosclerotic progression via inhibiting of vascular inflammatory responses implying the potential therapeutic action of evogliptin on the atherosclerotic complication.